Doripenem: Difference between revisions

Revision as of 01:21, 26 December 2013

Doripenem
DORIBAX^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup carbapenem. It was launched byShionogi Co. of Japan under the brand name "Finibax" in 2005. It is particularly active against Pseudomonas aeruginosa.

US Brand Names

Doribax^®

FDA Package Insert

Mechanisms of Action

References

@@ Line 1: / Line 1: @@
-{{SI}}
+__NOTOC__
+{{Doripenem}}
+{{CMG}}
+==Overview==
+Doripenem is an ultra-broad spectrum injectable [[antibiotic]]. It is a beta-lactam and belongs to the subgroup [[carbapenem]]. It was launched by[[Shionogi Co.]] of Japan under the [[brand name]] "[[Finibax]]" in 2005. It is particularly active against [[Pseudomonas aeruginosa]].
-Doripenem is an ultra-broad spectrum injectable [[antibiotic]]. It is a beta-lactam and belongs to the subgroup [[carbapenem]]. It was launched by [[Shionogi Co.]] of Japan under the [[brand name]] "[[Finibax]]" in 2005. It is particularly active against [[Pseudomonas aeruginosa]].
+==Category==
+Carbapenem
+==US Brand Names==
+Doribax<sup>®</sup>
+==FDA Package Insert==
+'''[[Doripenem description|Description]]'''
+'''| [[Doripenem clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Doripenem microbiology|Microbiology]]'''
+'''| [[Doripenem indications and usage|Indications and Usage]]'''
+'''| [[Doripenem contraindications|Contraindications]]'''
+'''| [[Doripenem warnings and precautions|Warnings and Precautions]]'''
+'''| [[Doripenem adverse reactions|Adverse Reactions]]'''
+'''| [[Doripenem overdosage|Overdosage]]'''
+'''| [[Doripenem clinical studies|Clinical Studies]]'''
+'''| [[Doripenem dosage and administration|Dosage and Administration]]'''
+'''| [[Doripenem compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
+'''| [[Doripenem directions for use|Directions For Use]]'''
+'''| [[Doripenem how supplied|How Supplied]]'''
+'''| [[Doripenem labels and packages|Labels and Packages]]'''
-According to the [[Centers for Disease Control and Prevention]] (CDC), two million Americans develop hospital-acquired infections each year, and approximately 90,000 die as a result. Approximately 70 percent of these infections are resistant to at least one antibiotic. Pneumonia is the second, most-common, hospital-acquired infection in the United States and is associated with substantial [[morbidity]] and [[mortality]].
+==Mechanisms of Action==
-Doripenem belongs to a class of antibacterial agents called carbapenems, which are useful in treating life-threatening infections caused by [[Gram-negative]] and [[Gram-positive]] bacteria. The data supporting the NDA showed doripenem was an effective treatment for hospital-acquired pneumonia. The data also demonstrated the effectiveness of doripenem against infections caused by Gram-negative bacteria, such as [[Pseudomonas aeruginosa]] and [[Enterobacteriaceae]], including strains of these bacteria that are resistant to other therapies.
+==References==
+{{Reflist|2}}
-Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections and, because of increasing multi-drug resistance, treatment options are limited. In general, there are few antibiotics available or currently in development to treat the resistant infections - which can be potentially life-threatening - associated with these Gram-negative bacteria.
+[[Category:Antibiotics]]
+[[Category:Wikinfect]]
-In clinical trials, doripenem was well-tolerated. The most common treatment-emergent adverse events seen were diarrhea, nausea, constipation, urinary tract infection and decubitus ulcer, commonly known as a bedsore.
-The [[nosocomial]] pneumonia indication for doripenem had been granted "fast-track" status by the FDA. Pending regulatory approval, doripenem will be marketed in the United States by [[Ortho-McNeil]], Inc. Doripenem is licensed from Shionogi & Co., Ltd., which launched the product in Japan in September 2005.
-[[Category:Carbapenem antibiotics]]
-[[es:Doripenem]]
-{{WH}}
-{{WS}}